Complete enrollment for the gastroparesis Phase III clinical study
Delivered after the deadline (126 days after the deadline)
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 10 Feb 2021
- Due
- 30 Jun 2021
- Delivered
- 3 Nov 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“The gastroparesis Phase III clinical study (VP-VLY-686-3301) is ongoing. The study has a target enrollment of 200 randomized patients and is expected to complete enrollment in the first half of 2021”
What we found
Evidence strength A What the grades mean
The company reported that enrollment for the gastroparesis Phase III study was complete in its November 2021 filings, which occurred after the first half of 2021 deadline.
-
A Vanda Pharmaceuticals Inc. 10-Q filed 2021-07-29
“The Phase III clinical study of tradipitant in gastroparesis is nearing completion with 95% of the target 200 patients already enrolled.” ✓ confirmed on the page
-
A Vanda Pharmaceuticals Inc. 8-K filed 2021-11-03
“Enrollment of the randomized portion of the Phase III clinical study of tradipitant in gastroparesis is complete.” ✓ confirmed on the page
Checked 25 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Complete
- Deliverable
- gastroparesis Phase III clinical study enrollment
- Target
- 200 patients
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
- Depends on
- Customer
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesClaude (Anthropic) re-read the evidence blind and read it as “Not met”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the recorded outcome.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Vanda Pharmaceuticals Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-VNDA-023458 · Corrections policy